Methods. A total of 238 patients with vasculitis from seven countries in Europe were evaluated at a single time point. Spearman's correlation coefficients were calculated between BVAS v. 3 scores, vasculitis activity index (VAI), physician's global assessment (PGA), the physician's treatment decision, CRP and the vasculitis damage index (VDI) to demonstrate that the BVAS v. 3 measures disease activity. Results. WG (63%), Churg-Strauss syndrome (9%) and microscopic polyangiitis (9%) were the most common diagnoses. The BVAS v. 3 showed convergent validity with the VAI [ = 0.82 (95% CI 0.77, 0.85)], PGA [ = 0.85 (95% CI 0.81, 0.88)] and the physician's treatment decision [ = 0.54 (95% CI 0.44, 0.62)]. There was little or no correlation between BVAS v. 3 and the CRP level [ = 0.18 (95% CI 0.05, 0.30)] or with the VDI [ = -0.10 (95% CI 0.22, 0.03)]. The inter-observer reliability was very high with an intra-class correlation coefficient (ICC) of 0.996 (95% CI 0.990, 0.998) for the total BVAS v. 3 score. Conclusion. The BVAS v. 3 has been evaluated in a large cohort of patients with vasculitis and the important properties of the tool revalidated. This study increases the utility of the BVAS v. 3 in different populations of patients with systemic vasculitis.

A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis / R. Suppiah, C. Mukhtyar, O. Flossmann, F. Alberici, B. Baslund, R. Batra, D. Brown, J. Holle, Z. Hruskova, D.R.W. Jayne, A. Judge, M.A. Little, A. Palmisano, C. Stegeman, V. Tesar, A. Vaglio, K. Westman, R. Luqmani. - In: RHEUMATOLOGY. - ISSN 1462-0324. - 50:5(2011 May), pp. 899-905. [10.1093/rheumatology/keq400]

A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis

F. Alberici;
2011

Abstract

Methods. A total of 238 patients with vasculitis from seven countries in Europe were evaluated at a single time point. Spearman's correlation coefficients were calculated between BVAS v. 3 scores, vasculitis activity index (VAI), physician's global assessment (PGA), the physician's treatment decision, CRP and the vasculitis damage index (VDI) to demonstrate that the BVAS v. 3 measures disease activity. Results. WG (63%), Churg-Strauss syndrome (9%) and microscopic polyangiitis (9%) were the most common diagnoses. The BVAS v. 3 showed convergent validity with the VAI [ = 0.82 (95% CI 0.77, 0.85)], PGA [ = 0.85 (95% CI 0.81, 0.88)] and the physician's treatment decision [ = 0.54 (95% CI 0.44, 0.62)]. There was little or no correlation between BVAS v. 3 and the CRP level [ = 0.18 (95% CI 0.05, 0.30)] or with the VDI [ = -0.10 (95% CI 0.22, 0.03)]. The inter-observer reliability was very high with an intra-class correlation coefficient (ICC) of 0.996 (95% CI 0.990, 0.998) for the total BVAS v. 3 score. Conclusion. The BVAS v. 3 has been evaluated in a large cohort of patients with vasculitis and the important properties of the tool revalidated. This study increases the utility of the BVAS v. 3 in different populations of patients with systemic vasculitis.
Disease activity; Outcomes research; Systemic vasculitis; Vasculitis; Wegener's granulomatosis
Settore MED/14 - Nefrologia
mag-2011
Article (author)
File in questo prodotto:
File Dimensione Formato  
21.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 148.83 kB
Formato Adobe PDF
148.83 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/646928
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 105
  • ???jsp.display-item.citation.isi??? 96
  • OpenAlex ND
social impact